PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsenterobacteriaceae infections
MeSH D004756 - enterobacteriaceae infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D016905:Gram-negative bacterial infections
29 Companies
14 Drugs
$
Success rate
D004756: 
Enterobacteriaceae infections
38 Companies
7 Drugs
$
Success rate
D004405:Bacillary dysentery
48 Companies
9 Drugs
$
Success rate
D004927:Escherichia coli infections
176 Companies
96 Drugs
$
Success rate
D006100:Granuloma inguinale
70 Companies
8 Drugs
$
Success rate
D007710:Klebsiella infections
163 Companies
75 Drugs
$
Success rate
D011512:Proteus infections
146 Companies
59 Drugs
$
Success rate
D012480:Salmonella infections
88 Companies
23 Drugs
$
Success rate
D015009:Yersinia infections
0 Companies
0 Drugs
Success rate
D016868:Serratia infections
60 Companies
14 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaSulfamethoxazole, Trimethoprim Cotrim  1985-05-16   
Sulfamethoxazole, Trimethoprim Cotrim D.s  1985-03-18   
Sulfamethoxazole, Trimethoprim Sulfamethoxazole Trimethoprim  1991-10-31   
Glenmark PharmaceuticalsSulfamethoxazole, Trimethoprim Sulfamethoxazole Trimethoprim  2010-12-22   
MylanSulfamethoxazole, Trimethoprim Sulfamethoxazole Trimethoprim  2017-08-30   
RochePhenazopyridine, Sulfamethoxazole Azo Gantanol  1987-09-10   
Sulfamethoxazole Gantanol  1982-01-01   
Lupin ResearchSulfamethoxazole, Trimethoprim Sulfamethoxazole Trimethoprim  2021-01-05   
AlpharmaSulfamethoxazole, Trimethoprim Trimeth/sulfa  1988-05-23   
Merck & CoCilastatin, Imipenem Primaxin  1987-01-08 $212 M Y2023 
Cilastatin, Imipenem, Relebactam Recarbrio 2033-03-21 2019-07-16   
Aurobindo PharmaSulfamethoxazole, Trimethoprim Sulfamethoxazole Trimethoprim  2010-02-16   
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
0%
0/0
Phase 2
0%
0/0
Phase 3
100%
3/3
Approved: 3Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Roche
Sulfamethoxazole
Merck & Co
Cilastatin,
Imipenem,
Relebactam
Eli Lilly
Sulfadiazine,
Sulfadiazine, silver
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use